Top

Published in:

14-10-2022 | Community-Acquired Pneumonia | IM - ORIGINAL

Serum TRAIL predicts severity and prognosis in patients with community-acquired pneumonia: a prospective cohort study

Authors: Dong-Xu Hua, Kai-Shu Ma, Jia-Yi Cheng, Ying Liu, Jing Sun, Qi-Yuan He, You-Peng Deng, Jin Yang, Lin Fu, Hui Zhao

Published in: Internal and Emergency Medicine | Issue 8/2022

Abstract

Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) can trigger the apoptosis pathways through binding to relative death receptors. However, the relationship of TRAIL with community-acquired pneumonia (CAP) was unclear. This study aims at exploring the relationships between circulatory TRAIL with severity and prognosis in CAP patients through a prospective cohort study. The whole of 239 CAP patients was enrolled. Demographic characteristics and clinical information were analyzed. TRAIL and inflammatory cytokines were measured using enzyme-linked immunosorbent assay (ELISA). Circulatory TRAIL was gradually increased in accord with CAP severity scores. Spearman or Pearson correlative analysis indicated that circulatory TRAIL was strongly associated with physiologic indicators among CAP patients. Mixed logistic and linear regression models revealed that circulatory TRAIL was positively correlated with the severity scores in CAP patients. After adjusting for confounders, higher levels of circulatory TRAIL on admission significantly elevated the risks of ICU admission, mechanical ventilation, longer hospital stays, or even death during hospitalization. The predictive capacities of serum TRAIL for death were higher compared with CAP severity scores, inflammatory and infectious indicators. There are obviously positive dose-response relationships between circulatory TRAIL on admission with the severity and poor prognostic outcomes in CAP patients. Circulatory TRAIL on admission may be used as a potential biomarker in predicting the severity and poor prognosis for CAP patients.

Available only for authorised users

Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC et al (2007) Infectious diseases society of America/American thoracic society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 44(Suppl 2(Suppl 2)):S27-72. https://doi.org/10.1086/511159CrossRefPubMed

Ramirez JA, Wiemken TL, Peyrani P, Arnold FW, Kelley R, Mattingly WA et al (2017) adults hospitalized with Pneumonia in the United States: incidence, epidemiology, and mortality. Clin Infect Dis 65(11):1806–1812. https://doi.org/10.1093/cid/cix647CrossRefPubMed

Liapikou A, Ferrer M, Polverino E, Balasso V, Esperatti M, Piñer R et al (2009) Severe community-acquired pneumonia: validation of the infectious diseases society of America/American thoracic society guidelines to predict an intensive care unit admission. Clin Infect Dis 48(4):377–385. https://doi.org/10.1086/596307CrossRefPubMed

Torres A, Cillóniz C, Ferrer M, Gabarrús A, Polverino E, Villegas S et al (2015) Bacteraemia and antibiotic-resistant pathogens in community acquired pneumonia: risk and prognosis. Eur Respir J 45(5):1353–1363. https://doi.org/10.1183/09031936.00152514CrossRefPubMed

Yuan X, Gajan A, Chu Q, Xiong H, Wu K, Wu GS (2018) Developing TRAIL/TRAIL death receptor-based cancer therapies. Cancer Metastasis Rev 37(4):733–748. https://doi.org/10.1007/s10555-018-9728-yCrossRefPubMedPubMedCentral

Sun P, Hu Z, Pan B, Lu X (2021) Targeting of keloid with TRAIL and TRAIL-R2/DR5. J Dermatolog Treat 32(8):957–964. https://doi.org/10.1080/09546634.2020.1714541CrossRefPubMed

Kemp TJ, Moore JM, Griffith TS (2004) Human B cells express functional TRAIL/Apo-2 ligand after CpG-containing oligodeoxynucleotide stimulation. J Immunol 173(2):892–899. https://doi.org/10.4049/jimmunol.173.2.892CrossRefPubMed

Zamai L, Ahmad M, Bennett IM, Azzoni L, Alnemri ES, Perussia B (1998) Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and fas ligand by immature and mature primary human NK cells. J Exp Med 188(12):2375–2380. https://doi.org/10.1084/jem.188.12.2375CrossRefPubMedPubMedCentral

Gandini M, Gras C, Azeredo EL, Pinto LM, Smith N, Despres P et al (2013) Dengue virus activates membrane TRAIL relocalization and IFN-α production by human plasmacytoid dendritic cells in vitro and in vivo. PLoS Negl Trop Dis 7(6):e2257. https://doi.org/10.1371/journal.pntd.0002257CrossRefPubMedPubMedCentral

10.

Trauzold A, Siegmund D, Schniewind B, Sipos B, Egberts J, Zorenkov D et al (2006) TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma. Oncogene 25(56):7434–7439. https://doi.org/10.1038/sj.onc.1209719CrossRefPubMed

11.

Secchiero P, Zerbinati C, Rimondi E, Corallini F, Milani D, Grill V et al (2004) TRAIL promotes the survival, migration and proliferation of vascular smooth muscle cells. Cell Mol Life Sci 61(15):1965–1974. https://doi.org/10.1038/sj.onc.1209719CrossRefPubMed

12.

Azab NA, Rady HM, Marzouk SA (2012) Elevated serum TRAIL levels in scleroderma patients and its possible association with pulmonary involvement. Clin Rheumatol 31(9):1359–1364. https://doi.org/10.1007/s10067-012-2023-3CrossRefPubMed

13.

Gochuico BR, Zhang J, Ma BY, Marshak-Rothstein A, Fine A (2000) TRAIL expression in vascular smooth muscle. Am J Physiol Lung Cell Mol Physiol 278(5):L1045-1050. https://doi.org/10.1152/ajplung.2000.278.5.L1045CrossRefPubMed

14.

Lawrie A, Waterman E, Southwood M, Evans D, Suntharalingam J, Francis S et al (2008) Evidence of a role for osteoprotegerin in the pathogenesis of pulmonary arterial hypertension. Am J Pathol 172(1):256–264. https://doi.org/10.2353/ajpath.2008.070395CrossRefPubMedPubMedCentral

15.

Brincks EL, Kucaba TA, Legge KL, Griffith TS (2008) Influenza-induced expression of functional tumor necrosis factor-related apoptosis-inducing ligand on human peripheral blood mononuclear cells. Hum Immunol 69(10):634–646. https://doi.org/10.1016/j.humimm.2008.07.012CrossRefPubMedPubMedCentral

16.

Kotelkin A, Prikhod’ko EA, Cohen JI, Collins PL, Bukreyev A (2003) Respiratory syncytial virus infection sensitizes cells to apoptosis mediated by tumor necrosis factor-related apoptosis-inducing ligand. J Virol 77(17):9156–9172. https://doi.org/10.1128/jvi.77.17.9156-9172.2003CrossRefPubMedPubMedCentral

17.

Droemann D, Hansen F, Aries SP, Braun J, Zabel P, Dalhoff K, Schaaf B (2006) Neutrophil apoptosis, activation and anti-inflammatory cytokine response in granulocyte colony-stimulating factor-treated patients with community-acquired pneumonia. Respiration 73(3):340–346. https://doi.org/10.1159/000090342CrossRefPubMed

18.

Rai P, Parrish M, Tay IJ, Li N, Ackerman S, He F et al (2015) Streptococcus pneumoniae secretes hydrogen peroxide leading to DNA damage and apoptosis in lung cells. Proc Natl Acad Sci U S A 112(26):E3421-3430. https://doi.org/10.1073/pnas.1424144112CrossRefPubMedPubMedCentral

19.

Li S, Zhang Y, Guan Z, Li H, Ye M, Chen X et al (2020) SARS-CoV-2 triggers inflammatory responses and cell death through caspase-8 activation. Signal Transduct Target Ther 5(1):235. https://doi.org/10.1038/s41392-020-00334-0CrossRefPubMedPubMedCentral

20.

Jiang X, Huang CM, Feng CM, Xu Z, Fu L, Wang XM (2021) Associations of serum S100A12 with severity and prognosis in patients with community-acquired pneumonia: a prospective cohort study. Front Immunol 12:714026. https://doi.org/10.3389/fimmu.2021.714026CrossRefPubMedPubMedCentral

21.

Wang JL, Chen X, Xu Y, Chen YX, Wang J, Liu YL et al (2021) The associations of serum il-37 with the severity and prognosis in patients with community-acquired pneumonia: a retrospective cohort study. Front Immunol 12:636896. https://doi.org/10.3389/fimmu.2021.636896CrossRefPubMedPubMedCentral

22.

Cao LF, Cheng JY, Xu Z, Feng CM, Zhao H, Wang XM et al (2022) Serum 8-hydroxydeoxyguanosine is a potential indicator for the severity and prognosis in patients with community-acquired pneumonia: a prospective cohort study. J Immunol 208(2):321–327. https://doi.org/10.4049/jimmunol.2100711CrossRefPubMed

23.

Jiang YL, Liu HY, Tang MM, Cheng JY, Zhao H, Fu L (2022) Serum level of 4-hydroxynonenal in community-acquired pneumonia: a potential biomarker for severity and prognosis. Front Med 9:798343. https://doi.org/10.3389/fmed.2022.798343CrossRef

24.

Zheng L, Fei J, Feng CM, Xu Z, Fu L, Zhao H (2021) Serum 8-iso-PGF2α predicts the severity and prognosis in patients with community-acquired pneumonia: a retrospective cohort study. Front Med (Lausanne) 8:633442. https://doi.org/10.3389/fmed.2021.633442CrossRef

25.

Feng CM, Cheng JY, Xu Z, Liu HY, Xu DX, Fu L et al (2021) Associations of serum resistin with the severity and prognosis in patients with community-acquired pneumonia. Front Immunol 12:703515. https://doi.org/10.3389/fimmu.2021.703515CrossRefPubMedPubMedCentral

26.

Liu HY, Xiang HX, Xiang Y, Xu Z, Feng CM, Fei J et al (2021) The associations of serum S100A9 with the severity and prognosis in patients with community-acquired pneumonia: a prospective cohort study. BMC Infect Dis 21(1):327. https://doi.org/10.1186/s12879-021-06020-yCrossRefPubMedPubMedCentral

27.

Xu Z, Wang XM, Cao P, Zhang C, Feng CM, Zheng L et al (2022) Serum IL-27 predicts the severity and prognosis in patients with community-acquired pneumonia: a prospective cohort study. Int J Med Sci 19(1):74–81. https://doi.org/10.7150/ijms.67028CrossRefPubMedPubMedCentral

28.

Fu L, Zhao H, Xiang Y, Xiang HX, Hu B, Tan ZX et al (2021) Reactive oxygen species-evoked endoplasmic reticulum stress mediates 1-nitropyrene-induced epithelial-mesenchymal transition and pulmonary fibrosis. Environ Pollut 283:117134. https://doi.org/10.1016/j.envpol.2021.117134CrossRefPubMed

29.

Fei J, Fu L, Cao W, Hu B, Zhao H, Li JB (2019) Low vitamin D status is associated with epithelial-mesenchymal transition in patients with chronic obstructive pulmonary disease. J Immunol 203(6):1428–1435. https://doi.org/10.4049/jimmunol.1900229CrossRefPubMed

30.

Qin HY, Li MD, Xie GF, Cao W, Xu DX, Zhao H et al (2022) Associations among S100A4, sphingosine-1-phosphate, and pulmonary function in patients with chronic obstructive pulmonary disease. Oxid Med Cell Longev 2022:6041471. https://doi.org/10.1155/2022/6041471CrossRefPubMedPubMedCentral

31.

Collison A, Foster PS, Mattes J (2009) Emerging role of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) as a key regulator of inflammatory responses. Clin Exp Pharmacol Physiol 36(11):1049–1053. https://doi.org/10.1111/j.1440-1681.2009.05258.xCrossRefPubMed

32.

Herold S, Steinmueller M, von Wulffen W, Cakarova L, Pinto R, Pleschka S et al (2008) Lung epithelial apoptosis in influenza virus pneumonia: the role of macrophage-expressed TNF-related apoptosis-inducing ligand. J Exp Med 205(13):3065–3077. https://doi.org/10.1084/jem.20080201CrossRefPubMedPubMedCentral

33.

Liu H, Yang E, Lu X, Zuo C, He Y, Jia D et al (2015) Serum levels of tumor necrosis factor-related apoptosis-inducing ligand correlate with the severity of pulmonary hypertension. Pulm Pharmacol Ther 33:39–46. https://doi.org/10.1016/j.pupt.2015.06.002CrossRefPubMed

34.

Hameed AG, Arnold ND, Chamberlain J, Pickworth JA, Paiva C, Dawson S et al (2012) Inhibition of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) reverses experimental pulmonary hypertension. J Exp Med 209(11):1919–1935. https://doi.org/10.1084/jem.20112716CrossRefPubMedPubMedCentral

35.

Wu Y, Shen Y, Zhang J, Wan C, Wang T, Xu D et al (2015) Increased serum TRAIL and DR5 levels correlated with lung function and inflammation in stable COPD patients. Int J Chron Obstruct Pulmon Dis 10:2405–2412. https://doi.org/10.2147/COPDS92260CrossRefPubMedPubMedCentral

36.

Akram KM, Lomas NJ, Forsyth NR, Spiteri MA (2014) Alveolar epithelial cells in idiopathic pulmonary fibrosis display upregulation of TRAIL, DR4 and DR5 expression with simultaneous preferential over-expression of pro-apoptotic marker p53. Int J Clin Exp Pathol 7(2):552–564PubMedPubMedCentral

37.

Fu L, Li XY, Fei J, Xiang Y, Xiang HX, Li MD et al (2020) Myocardial injury at early stage and its association with the risk of death in COVID-19 patients: a hospital-based retrospective cohort study. Front Cardiovasc Med 7:590688. https://doi.org/10.3389/fcvm.2020.590688CrossRefPubMedPubMedCentral

38.

Fu L, Fei J, Xu S, Xiang HX, Xiang Y, Hu B et al (2020) Liver dysfunction and its association with the risk of death in COVID-19 patients: a prospective cohort study. J Clin Transl Hepatol 8(3):246–254. https://doi.org/10.14218/JCTH.2020.00043CrossRefPubMedPubMedCentral

39.

Xiang HX, Fei J, Xiang Y, Xu Z, Zheng L, Li XY et al (2021) Renal dysfunction and prognosis of COVID-19 patients: a hospital-based retrospective cohort study. BMC Infect Dis 21(1):158. https://doi.org/10.1186/s12879-021-05861-xCrossRefPubMedPubMedCentral

40.

Kazama I (2020) Targeting lymphocyte Kv1.3-channels to suppress cytokine storm in severe COVID-19: can it be a novel therapeutic strategy? Drug Discov Ther. 14(3):143–144. https://doi.org/10.5582/ddt.2020.03046CrossRefPubMed

41.

Zhang Y, Zhong Y, Pan L, Dong J (2020) Treat 2019 novel coronavirus (COVID-19) with IL-6 inhibitor: are we already that far? Drug Discov Ther 14(2):100–102. https://doi.org/10.5582/ddt.2020.03006CrossRefPubMed

42.

Gundlach JP, Hauser C, Schlegel FM, Böger C, Röder C, Röcken C et al (2018) Cytoplasmic TRAIL-R1 is a positive prognostic marker in PDAC. BMC Cancer 18(1):777. https://doi.org/10.1186/s12885-018-4688-8CrossRefPubMedPubMedCentral

43.

Heilmann T, Vondung F, Borzikowsky C, Szymczak S, Krüger S, Alkatout I et al (2019) Heterogeneous intracellular TRAIL-receptor distribution predicts poor outcome in breast cancer patients. J Mol Med (Berl) 97(8):1155–1167. https://doi.org/10.1007/s00109-019-01805-wCrossRef

44.

Liabeuf S, Barreto DV, Barreto FC, Chasseraud M, Brazier M, Choukroun G et al (2010) The circulating soluble TRAIL is a negative marker for inflammation inversely associated with the mortality risk in chronic kidney disease patients. Nephrol Dial Transplant 25(8):2596–2602. https://doi.org/10.1093/ndt/gfq042CrossRefPubMed

Title: Serum TRAIL predicts severity and prognosis in patients with community-acquired pneumonia: a prospective cohort study
Authors: Dong-Xu Hua
Kai-Shu Ma
Jia-Yi Cheng
Ying Liu
Jing Sun
Qi-Yuan He
You-Peng Deng
Jin Yang
Lin Fu
Hui Zhao
Publication date: 14-10-2022
Publisher: Springer International Publishing
Keywords: Community-Acquired Pneumonia
Bronchitis
Published in: Internal and Emergency Medicine / Issue 8/2022
Print ISSN: 1828-0447
Electronic ISSN: 1970-9366
DOI: https://doi.org/10.1007/s11739-022-03086-7

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2022

Factors associated with colorectal cancer screening adherence and the impact of COVID-19 on screening patterns in Connecticut, USA

A man with fever and cogwheel-like dermal lesions

Some concerts about incidence and outcomes of in-hospital cardiac arrest in obstetric setting

Infections as predictors of NAFLD progression

Comparison between the first and second COVID-19 waves in Internal Medicine wards in Milan, Italy: a retrospective observational study

Impact of thyroid function screening in a large cohort of patients admitted to an emergency department

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials